Interacting Drugs |
Butalbital compound vs Tositumomab and Iodine I 131 Tositumomab |
Security Level |
|
Mechanism |
Tositumomab and Iodine I 131 Tositumomab: Antiplatelet Agents may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased. |
Management |
Monitor therapy |
Butalbital compound vs Tositumomab and Iodine I 131 Tositumomab
Post Review about Butalbital compound vs Tositumomab and Iodine I 131 Tositumomab Click here to cancel reply.
Other Interactions of Butalbital compound
Other Interactions of Tositumomab and Iodine I 131 Tositumomab
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.